ArticleChildren (Basel, Switzerland)2018
Alanine Aminotransferase as a Monitoring Biomarker in Children with Nonalcoholic Fatty Liver Disease: A Secondary Analysis Using TONIC Trial Data.
Article in Children (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease.Clinical and molecular hepatology · 2024Guideline
- Randomized placebo-controlled trial of losartan for pediatric NAFLD.Hepatology (Baltimore, Md.) · 2022Trial
- Trial
- MASLD In Children - A Distinct Phenotype?Current obesity reports · 2026Review
- Biomarkers in Disease Diagnosis and Monitoring: Insights into Clinical Applications and Mass Spectrometry-based Detection.Applied biochemistry and biotechnology · 2026Review
- Fighting the epidemic of pediatric metabolic dysfunction-associated steatotic liver disease: Role of non-invasive diagnostics and early pharmacological intervention.World journal of hepatology · 2026Review
- Real-World Assessment of Liver Corrected T1 and Magnetic Resonance Elastography in Predicting Liver Disease Progression.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- Leukocyte cell-derived chemotaxin 2 correlates with pediatric non-alcoholic fatty liver disease.Clinical and translational science · 2023Article
- Noninvasive biomarkers in pediatric nonalcoholic fatty liver disease.World journal of hepatology · 2023Review
- BMI Metrics Are Poor Predictors of Pediatric Nonalcoholic Fatty Liver Disease Severity.Childhood obesity (Print) · 2023Article
- Biomarkers: Promising and valuable tools towards diagnosis, prognosis and treatment of Covid-19 and other diseases.Heliyon · 2023Review
- Endocrine disrupting chemicals: A promoter of non-alcoholic fatty liver disease.Frontiers in public health · 2023Review
- Variation in Alanine Aminotransferase in Children with Non-Alcoholic Fatty Liver Disease.Children (Basel, Switzerland) · 2022Article
- The association between urinary bisphenol A levels and nonalcoholic fatty liver disease in Korean adults: Korean National Environmental Health Survey (KoNEHS) 2015-2017.Environmental health and preventive medicine · 2021Article
- Can Baseline Characteristics be Used to Predict Liver Disease Outcomes in Pediatric Nonalcoholic Fatty Liver Disease?Obesity (Silver Spring, Md.) · 2021Article
- Perspectives on youth-onset nonalcoholic fatty liver disease.Endocrinology, diabetes & metabolism · 2020Review
- Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease.Metabolism: clinical and experimental · 2020Review
- Association of theNutrients · 2020Article
- Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease.Gastroenterology · 2019Article
- A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health.Frontline gastroenterology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundValidated noninvasive biomarkers to assess treatment response in pediatric nonalcoholic fatty liver disease (NAFLD) are lacking. We aimed to validate alanine aminotransferase (ALT), a monitoring biomarker for change in liver histology.
methodsA retrospective analysis using data from the TONIC trial. NAFLD histologic assessments were defined by: Fibrosis score, NAFLD activity score (NAS), nonalcoholic steatohepatitis (NASH), and a combination of NASH resolution and fibrosis (NASH + fibrosis). Analysis was performed using classification and regression trees (CART) as well as logistic regression.
resultsMean ALT for the child over 96 weeks and percent change of ALT from baseline to 96 weeks were significant predictors of progression of NAFLD for each histologic assessment (
conclusionMean ALT over 96 weeks is a reasonable proxy of histologic improvement of NASH and NASH + fibrosis. These findings support ALT as a valid monitoring biomarker of histologic change over time in children with NASH and fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.